Amy Trevvett

Public Communications Contact at DICERNA PHARMACEUTICALS, INC.

Health Technology

Profile

Amy Trevvett is currently the Head of Media Relations at Dicerna Pharmaceuticals, Inc. She previously worked as the Director of Corporate Communications at Sumitomo Pharma America, Inc. and as the VP of Corporate Communications and Investor Relations at Alaunos Therapeutics, Inc.

Amy Trevvett active positions

Companies	Position	Start
DICERNA PHARMACEUTICALS, INC.	Public Communications Contact	-

All active positions of Amy Trevvett

Former positions of Amy Trevvett

Companies	Position	End
ALAUNOS THERAPEUTICS, INC.	Public Communications Contact	-
Sumitomo Pharma America, Inc. Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.	Investor Relations Contact	-

See the detail of Amy Trevvett's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Amy Trevvett's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ALAUNOS THERAPEUTICS, INC.	Health Technology

Private companies	2
Sumitomo Pharma America, Inc. Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.	Health Technology
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.	Health Technology